Key Regulatory Considerations for the Development of Biosimilar Pharmaceutical Products

Journal Title: IOSR Journal of Pharmacy (IOSRPHR) - Year 2014, Vol 4, Issue 2

Abstract

  Regulatory authorities are faced with different kinds of challenges when dealing with biosimilar products compared to other conventional generics. This is one of the reasons which made the FDA in the U.S. to delay authorizing biosimilars which have been in existence in Europe since 2005. Legal and scientific issues were sorted out in 2007 thus allowing the U.S. to approve Omnitrope and Valtropin. The BPCI Act was signed into law in 2009 and it was responsible for creating biological drug approval. Other important components of biosimilars are data exclusivity and patents whose aim are to preserve knowledge and innovation. They recognizes that an originator invest a lot of time and resources before producing a product. This document ends by discussing the challenges and opportunities of producing biosimilar products, and the issues to be considered before developing a biosimilar product.

Authors and Affiliations

Samrat Sisodia

Keywords

Related Articles

Corrosion Inhibition Effect of Flower of Euphorbia Caducifolia for Iron in Acid Media

ABSTRACT: Corrosion is a natural process. It is gradual destruction of metal by chemical or electrochemical reaction with their environment. It may be prevented by either alloying or by anti rust solutions. The naturally...

 Anemia and Iron Deficiency Anemia in Egypt

 Blood hemoglobin and serum ferritin analysis were used to identify the extent of anemia and iron deficiency anemia in Egypt. The study conducted in 2010/11, among 4526 households from eleven governorates and...

 Hepatoprotective effects of simvastatin on paracetamol -induced hepatic damage in rats

 ABSTRACT: This study was designed to investigate the possibility of statins hepatoprotection in paracetamol toxicicity. Paracetamol hepatotoxicity was associated with significant decrease in the serum total&nb...

Emotional Maturity and General Well-Being of Adolescents

This study aimed to find the relationship between emotional maturity and general well-being of adolescents. Adolescence is the period of transition from child hood to adulthood, where there are various changes in all the...

Download PDF file
  • EP ID EP115645
  • DOI -
  • Views 113
  • Downloads 0

How To Cite

Samrat Sisodia (2014).  Key Regulatory Considerations for the Development of Biosimilar Pharmaceutical Products. IOSR Journal of Pharmacy (IOSRPHR), 4(2), 24-26. https://europub.co.uk./articles/-A-115645